Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock Price Up 7.1% – Still a Buy?

Posted by Brian Himes on Aug 28th, 2026

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report)’s share price shot up 7.1% on Wednesday . The stock traded as high as $550.33 and last traded at $548.71. Approximately 172,602 shares changed hands during trading, a decline of 50% from the average daily volume of 347,942 shares. The stock had previously closed at $512.16.

Analyst Ratings Changes

MDGL has been the topic of several recent research reports. Wells Fargo & Company started coverage on Madrigal Pharmaceuticals in a research report on Monday, July 27th. They issued an “overweight” rating and a $685.00 price objective on the stock. Citigroup reaffirmed an “outperform” rating on shares of Madrigal Pharmaceuticals in a research note on Friday, July 17th. HC Wainwright reiterated a “buy” rating on shares of Madrigal Pharmaceuticals in a report on Friday, July 31st. Barclays decreased their target price on shares of Madrigal Pharmaceuticals from $964.00 to $962.00 and set an “overweight” rating on the stock in a research report on Monday, August 3rd. Finally, Canaccord Genuity Group boosted their price target on Madrigal Pharmaceuticals from $578.00 to $587.00 and gave the company a “buy” rating in a report on Wednesday, July 29th. Fifteen equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $699.64.

Get Our Latest Research Report on Madrigal Pharmaceuticals

Madrigal Pharmaceuticals Trading Up 0.9%

The stock has a market capitalization of $12.56 billion, a price-to-earnings ratio of -42.18 and a beta of -1.01. The company has a debt-to-equity ratio of 0.65, a current ratio of 3.20 and a quick ratio of 2.94. The business’s 50-day simple moving average is $526.40 and its two-hundred day simple moving average is $502.54.

Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported ($1.99) EPS for the quarter, topping analysts’ consensus estimates of ($2.68) by $0.69. The company had revenue of $364.25 million for the quarter, compared to analysts’ expectations of $352.13 million. Madrigal Pharmaceuticals had a negative return on equity of 56.65% and a negative net margin of 25.32%.The firm’s quarterly revenue was up 71.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($1.90) earnings per share. On average, research analysts anticipate that Madrigal Pharmaceuticals, Inc. will post -7.03 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, General Counsel Shannon T. Kelley sold 664 shares of Madrigal Pharmaceuticals stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $514.97, for a total transaction of $341,940.08. Following the sale, the general counsel owned 11,474 shares in the company, valued at $5,908,765.78. This trade represents a 5.47% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider David Soergel sold 1,042 shares of the business’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $495.74, for a total transaction of $516,561.08. Following the transaction, the insider directly owned 10,033 shares in the company, valued at approximately $4,973,759.42. The trade was a 9.41% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 17.60% of the company’s stock.

Institutional Trading of Madrigal Pharmaceuticals

Large investors have recently modified their holdings of the business. Persistent Asset Partners Ltd acquired a new position in shares of Madrigal Pharmaceuticals in the second quarter worth about $29,000. Global Retirement Partners LLC purchased a new stake in Madrigal Pharmaceuticals during the 2nd quarter worth approximately $34,000. Kemnay Advisory Services Inc. acquired a new position in shares of Madrigal Pharmaceuticals in the 4th quarter valued at approximately $39,000. Quarry LP acquired a new position in shares of Madrigal Pharmaceuticals in the 3rd quarter valued at approximately $39,000. Finally, Johnson Financial Group Inc. purchased a new position in shares of Madrigal Pharmaceuticals during the 3rd quarter valued at approximately $50,000. 98.50% of the stock is currently owned by institutional investors and hedge funds.

About Madrigal Pharmaceuticals

(Get Free Report)

Madrigal Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for cardiovascular, metabolic and liver diseases. The company’s pipeline centers on novel, liver-directed agents designed to address significant unmet medical needs, with an emphasis on nonalcoholic steatohepatitis (NASH) and related metabolic disorders.

The lead product candidate, resmetirom (MGL-3196), is an orally administered, selective thyroid hormone receptor-β agonist in Phase 3 development for the treatment of NASH.